دورية أكاديمية
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
| العنوان: | Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial |
|---|---|
| المؤلفون: | Holman, Rury R., Coleman, Roth L., Chan, Juliana C. N., Chiasson, Jean-Louis, Feng, Huimei, Ge, Junbo, Gerstein, Hertzel C., Gray, Richard, Huo, Yong, Lang, Zhihui, McMurray, John, Ryden, Lars, Schroeder, Stefan, Sun, Yihong, Theodorakis, Michael J., Tendera, Michal, Tucker, Lynne, Tuomilehto, Jaakko, Wei, Yidong, Yang, Wenying, Wang, Duolao, Hu, Dayi, Pan, Changyu |
| المساهمون: | Holman, RR (reprint author), Churchill Hosp, Diabet Trials Unit, Oxford OX3 7LJ, England., Univ Oxford, Diabet Trials Unit, Oxford, England., Univ Oxford, MRC Populat Hlth Res Unit, Oxford, England., Chinese Univ Hong Kong, Prince Wales Hosp Shatin, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China., Univ Montreal, Ctr Rech, Ctr Hosp, Dept Med, Montreal, PQ, Canada., Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China., McMaster Univ, Dept Med & Populat, Hlth Res Inst, Hamilton, ON, Canada., Hamilton Hlth Sci, Hamilton, ON, Canada., Peking Univ, Hosp 1, Dept Cardiol, Beijing, Peoples R China., Bayer Healthcare Co Ltd, Beijing, Peoples R China., Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland., Karolinska Inst, Dept Med K2, Stockholm, Sweden., Bayer AG, Pharma Div, Berlin, Germany., China Japan Friendship Hosp, Beijing, Peoples R China., Med Univ Silesia, Sch Med Katowice, Dept Cardiol & Struct Heart Dis, Katowice, Poland., Dasman Diabet Inst, Dasman, Kuwait., Danube Univ Krems, Dept Neurosci & Prevent Med, Krems, Austria., Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland., King Abdulaziz Univ, Jeddah, Saudi Arabia., Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Shanghai, Peoples R China., Univ Liverpool Liverpool Sch Trop Med, Trop Clin Trials Unit, Liverpool, Merseyside, England., Peking Univ, Peoples Hosp, Beijing, Peoples R China., Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China., Churchill Hosp, Diabet Trials Unit, Oxford OX3 7LJ, England. |
| المصدر: | SCI |
| بيانات النشر: | LANCET DIABETES & ENDOCRINOLOGY |
| سنة النشر: | 2017 |
| المجموعة: | Peking University Institutional Repository (PKU IR) / 北京大学机构知识库 |
| مصطلحات موضوعية: | GLUCAGON-LIKE PEPTIDE-1, MYOCARDIAL-INFARCTION, LONG-TERM, FOLLOW-UP, PREVENTION, NIDDM, RISK, HYPERTENSION, PROGRESSION, FAILURE |
| الوصف: | Background The effect of the alpha-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced. Methods The Acarbose Cardiovascular Evaluation (ACE) trial was a randomised, double-blind, placebo-controlled, phase 4 trial, with patients recruited from 176 hospital outpatient clinics in China. Chinese patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1), in blocks by site, by a centralised computer system to receive oral acarbose (50 mg three times a day) or matched placebo, which was added to standardised cardiovascular secondary prevention therapy. All study staff and patients were masked to treatment group allocation. The primary outcome was a five-point composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospital admission for unstable angina, and hospital admission for heart failure, analysed in the intention-to-treat population (all participants randomly assigned to treatment who provided written informed consent). The secondary outcomes were a three-point composite outcome (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), death from any cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, development of diabetes, and development of impaired renal function. The safety population comprised all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513. Findings Between March 20, 2009, and Oct 23, ... |
| نوع الوثيقة: | journal/newspaper |
| اللغة: | English |
| تدمد: | 2213-8587 |
| العلاقة: | LANCET DIABETES & ENDOCRINOLOGY. 2017, 5(11), 877-886.; 1938594; http://hdl.handle.net/20.500.11897/484539Test; WOS:000413782300020 |
| DOI: | 10.1016/S2213-8587(17)30309-1 |
| الإتاحة: | https://doi.org/20.500.11897/484539Test https://doi.org/10.1016/S2213-8587Test(17)30309-1 https://hdl.handle.net/20.500.11897/484539Test |
| رقم الانضمام: | edsbas.759B5F1 |
| قاعدة البيانات: | BASE |
| تدمد: | 22138587 |
|---|---|
| DOI: | 10.1016/S2213-8587(17)30309-1 |